Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in ...

Earnings Estimate Revisions for Q32 Bio This gene editing company is expected to earn -$5.50 per share for the fiscal year ending December 2024, which represents a year-over-year change of 83.2%.

Earnings Estimate Revisions for Q32 Bio This gene editing company is expected to earn -$4.14 per share for the fiscal year ending December 2025, which represents a year-over-year change of 37.1%.

Q32 Bio Inc. (NASDAQ:QTTB – Get Free Report) has been assigned an average recommendation of “Hold” from the eight research firms that are currently covering the company, Marketbeat.com reports.

SIGNAL-AA Part B topline data readout on-track for 1H'26 -- WALTHAM, Mass., April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage ...

(RTTNews) - Q32 Bio Inc. (QTTB) announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata (AA) at the 2025 American Academy ...

WALTHAM, MA – Q32 Bio Inc., a biopharmaceutical company focused on developing therapies for autoimmune and inflammatory diseases with a market capitalization of $23 million, announced today that ...

In a report released on April 16, Thomas Smith from Leerink Partners maintained a Hold rating on Q32 Bio (QTTB – Research Report). The company’s shares closed yesterday at $2.12. Discover ...